Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Determinants of ligand binding and catalytic activity in the myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase.
Evoked potentials in multiple sclerosis.
Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?
[Contrast agents in MRI-diagnosis of multiple sclerosis].
A modified superantigen rescues Ly6G(-)CD11b(+)blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE.
Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune mediated neuropathies.
Analysis of the direct injury effector of oligodendroglia cells or myelin sheath in an experimental allergic encephalomyelitis model induced by the MOG35-55 peptide.
Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence.
Therapeutic plasma exchange in neuromyelitis optica: A case series.
Critical role of activation induced cytidine deaminase in Experimental Autoimmune Encephalomyelitis.
Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?
Misoprostol as a Therapeutic Option for Trigeminal Neuralgia in Patients with Multiple Sclerosis.
Tobacco smoking and excess mortality in multiple sclerosis: a cohort study.
The genetics of multiple sclerosis: review of current and emerging candidates.
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.
Chromosomal radiosensitivity in patients with multiple sclerosis.
Early and Degressive Putamen Atrophy in Multiple Sclerosis.
Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Multiple sclerosis imaging: recent advances.
Neuroendocrine Responses to Transvascular Autonomic Modulation: A Modified Balloon Angioplasty in Multiple Sclerosis Patients.
Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis.
Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation.
[Ophthalmological Findings in Paediatric and Adolescent Multiple Sclerosis.]
Pages
« first
‹ previous
…
280
281
282
283
284
285
286
287
288
…
next ›
last »